Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Prostatic Neoplasms 56Breast Neoplasms 50Lung Neoplasms 31Neoplasms 20Neoplasm Metastasis 18Stomach Neoplasms 14Head and Neck Neoplasms 13Squamous Cell Carcinoma of Head and Neck 12Recurrence 7Pancreatic Neoplasms 7Ovarian Neoplasms 7Adenocarcinoma of Lung 7Sarcoma 6Esophageal Neoplasms 6Carcinoma, Transitional Cell 5Carcinoma, Squamous Cell 5Urinary Bladder Neoplasms 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Triple Negative Breast Neoplasms 3Advanced Non-Small Cell Lung Cancer 3Adenocarcinoma, Bronchiolo-Alveolar 3Solid Tumor 2Small Cell Lung Carcinoma 2Prostatic Neoplasms, Castration-Resistant 2Inflammatory Breast Neoplasms 2Hormone Refractory Prostate Cancer 2HER2-positive Breast Cancer 2Fallopian Tube Neoplasms 2

Interventions

rucaparib 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × ATM Gene Mutation × Docetaxel × Clear all
NCT03442556 2025-06-12

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

University of Washington

Phase 2 Terminated
18 enrolled
Genitourinary

ATM Gene Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡